

1 1. A peptide of eight to twenty amino acids in  
2 length which comprises a hydrophilic analog of an alpha-  
3 fetoprotein peptide having SEQ ID NO:6: EMTFVNPG.

1        3.    The peptide of claim 1 wherein the peptide is  
2 cyclic.

1        5.    The peptide of claim 1 which comprises an amino  
2 acid sequence selected from the group consisting of:

1        6.    The peptide of claim 1 labeled with a  
2 detectable marker.

1        7.    The peptide of claim 6 wherein the detectable  
2 marker is a radiolabel.

1        9.    A dimeric peptide consisting of two peptides of  
2 claim 1.

1        11. The dimeric peptide of claim 9, wherein the two  
2 peptides are SEQ ID NO:3 and SEQ ID NO:10.

1        12. A multimeric peptide consisting of three or  
2 more peptides of claim 1.

1        13. A composition comprising the peptide of claim 1,  
2 and a suitable carrier.

1        14. The composition of claim 13 wherein the  
2        suitable carrier includes a stabilization excipient.

1        15. The composition of claim 14 wherein the  
2        stabilization excipient is dodecyl maltoside or mannitol.

1        16. An antibody that specifically binds to the  
2 peptide of claim 1.

1        17. A method of reducing estrogen-stimulated growth  
2 of cells, the method comprising exposing cells to the  
3 peptide of claim 1.

1           18. The method of claim 17 which further comprises  
2 exposing the cells to tamoxifen before, during, or after  
3 exposing the cells to the peptide.

1        19. A method of treating or preventing cancer in a  
2 subject which comprises administering to the subject an  
3 amount of the peptide of claim 1 effective to treat or  
4 prevent cancer in the subject.

1        20. The method of claim 19 wherein the cancer is  
2 estrogen-dependent cancer.

1        21. The method of claim 20 wherein the estrogen-  
2 dependent cancer is breast cancer.

1        22. The method of claim 19 which further comprises  
2 administering a suitable amount of tamoxifen to the  
3 subject before, during, or after administering the  
4 peptide to the subject.

0987233 05004  
102090 232/860